Tonix Sees Mpox Vaccine Opportunity As A Potential Lifeline

The specialist pharma company hopes demand for mpox vaccines will help establish its vaccine platform, but cash and investor confidence remain in short supply.

Mpox hand
• Source: Shutterstock

The declaration of mpox as a public health emergency of international concern is seeing a handful of small companies benefit from urgent demand for vaccine supplies, and Tonix Pharmaceuticals is the latest to see a potential opportunity.

Key Takeaways

  • Tonix is looking to help meet demand for mpox vaccines – though its candidate TNX-801 is yet to commence Phase I studies.

The company has unveiled a new collaboration to advance TNX-801, a live replicating, attenuated virus vaccine based on horsepox currently...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Business

More from Scrip